Challenge to supplementary protection on Takeda ADHD drug falls flat in UK
A supplementary protection certificate which provided protection after patent expiry for the active ingredient in Takeda’s ADHD drug Elvanse in the UK was deemed valid there on Thursday. The ruling marks a...To view the full article, register now.
Already a subscriber? Click here to view full article